New-ATE-Logo2019 (1)

 

Expansion of Samsung Biologics' Business

Into Late Discovery/Early Development

Presenter:

11-14-2023-Samsung-ATE-Social-PromoDerrick Katayama
Lead Scientist, Formulation Development,
Samsung Biologics
 
Derrick Katayama is a lead scientist in the formulation group at Samsung Biologics, where he manages multiple biological molecule formulation projects. Derrick has over 15 years of experience in the biopharmaceutical industry and has held various positions at companies such as Amylin Pharmaceuticals Inc., MedImmune Inc., Boehringer Ingelheim, and Legacy BioDesign LLC.
 
During his time in the biopharmaceutical industry, Derrick has worked on a diverse range of projects, including liquid and lyophilized formulation and characterization of monoclonal antibodies, bispecific antibodies, recombinant proteins, protein subunit vaccine candidates, and synthetic peptides. Derrick received his doctoral degree in pharmaceutical sciences from the University of Colorado Health Sciences Center (UCHSC), with studies focused on understanding protein stability in both liquid and lyophilized states.